(Q35583599)

9 August 2017

1 reference

title

Metabolic syndrome - a new risk factor of coronary heart disease? (English)

1 reference

9 August 2017

Metabolic syndrome – a new risk factor of coronary heart disease? (English)

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

1 April 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

1 April 2024

author name string

S. Haffner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617221

1 April 2024

H. B. Cassells

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617221

1 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14617221

1 April 2024

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1463-1326.2003.00290.x

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1463-1326.2003.00290.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Diabetes, Obesity and Metabolism

1 April 2024

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

359-370

1 reference

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Factor analysis of ethnic variation in the multiple metabolic (insulin resistance) syndrome in three Canadian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

British Hypertension Society guidelines for hypertension management 1999: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Beyond blood pressure: the endothelium and atherosclerosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

The continuing epidemics of obesity and diabetes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

The continuing epidemic of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Effects of statins in reducing thrombotic risk and modulating plaque vulnerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00290.X

Associazione di iperlipemia, diabete mellito e obesita' di medio grado

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Epidermiology and associated risk factors of hyperlipoproteinemia

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Diagnosis of primary hyperlipoproteinemias

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Diabetes trends in the U.S.: 1990-1998.

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Childhood obesity: the health issue

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events

1 April 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Standards of medical care for patients with diabetes mellitus

1 April 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 April 2024

30

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Effects of current therapeutic interventions on insulin resistance

1 April 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

1 April 2024

35

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 April 2024

37

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

1 April 2024

41

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome

1 April 2024

43

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 April 2024

47

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

1 April 2024

49

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

The role of fibric acids in atherosclerosis

1 April 2024

53

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 April 2024

59

1 reference

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00290.X

1 April 2024

Identifiers

1 reference

9 August 2017

1 reference